Germany· DE-A57-b25d0a5d1f85e19b
Nimodipin Ethypharm
A nimodipine product containing nimodipine, registered in Germany by Altan Pharmaceuticals S.A.. The same ATC class is registered in 14 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Nimodipine is registered in 14 of 19 countries.
Countries holding a registration under ATC C08CA06 (nimodipine), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 8 of them publish a price we can compare per daily dose
Nimodipine · ATC C08CA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of nimodipine costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $5.28 in France to $7.99 in Switzerland — a ×1.5 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Nimodipine · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$7.99
- FR France$5.28
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Nimodipine
- Manufacturer
- Altan Pharmaceuticals S.A.
- Country
- Germany (DE)
- ATC code
- C08CA06
- ATC class
- Nimodipine
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
202 interactions on record for nimodipine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nimodipine · interactions on record
202 records
- 15 severe
- 164 moderate
- 1 minor
- 20 info
Most severe, free to view
- DolasetronA04AA04severe
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
2 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nimodipine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- PolandNimodipine AltanAltan Pharmaceuticals, S.A.
- CzechiaDILCERENZentiva, k.s., Praha
- FinlandNimotopOrifarm Oy
- SpainBRAINAL 30 mg COMPRIMIDOS RECUBIERTOS CON PELICULAAristo Pharma Iberia S.L.
- SwedenNimotop 0,2 mg/ml Infusionsvätska, lösningOrifarm AB
- United KingdomNimodipine 30mg/5ml oral suspensionSpecial Order
- United StatesnimodipineHeritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
- NorwayBrainalAristo Pharma
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Nimotop
- Belgium · Nimotop
- Bulgaria · Нимотоп S
- Cyprus · Nemotan
- Czechia · Dilceren, Nimotop S
- Denmark · Nimotop
- Estonia · Nimotop
- Spain · Brainal, Nimodipino Altan
- Finland · Nimotop
- France · Nimodipine Altan, Nimotop
- United Kingdom (Northern Ireland) · Nimotop
- Greece · Befimat, Curban
- Croatia · Nimotop S
- Ireland · Nimotop
- Italy · Iskidrop, Nimobrain
- Luxembourg · Nimotop
- Latvia · Nimotop
- Netherlands · Nimotop
- Norway · Nimotop
- Poland · Nimotop S
- Portugal · Brainox, Modina
- Romania · Nimotop
- Sweden · Nimotop
- Slovenia · Nimodipin Bayer, Nimodipin Laboratoire X.O
- Slovakia · Dilceren Pro Infusione, Nemotan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8f0f30ef-9bf1-4ccc-a912-a9fefe10c2b5 GET /v1/drugs/8f0f30ef-9bf1-4ccc-a912-a9fefe10c2b5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Intravenous Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Nimodipine",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about nimodipine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.